Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
New Publication – Insights into Frizzled/WNT Signalling with Salipro®
2026-10-19
Sometimes the lipids are part of the mechanism.
GPCRs are among the most important drug targets, and Salipro® enables their study in native-like lipid environments.
While previous detergent-based structures could not reveal the functional role of PIP2, in this recent preprint the researchers show that this lipid is an integral part of the Frizzled/WNT signaling mechanism itself. By studying the GPCR in Salipro®, the researchers were able to reveal lipid-protein interactions and a mechanism that promotes coupling between Frizzled and its intracellular signaling partner, Dishevelled.
This study also represents one of the first public GPCR structures generated using Salipro®, highlighting the importance of preserving native-like lipid environments when studying membrane proteins.
Congratulations to Gunnar Schulte and colleagues on this exciting contribution to GPCR and structural biology research!
Find the preprint here: G. Schulte, R. Shekhani, M. Scharf, et al., Conserved allosteric regulation of Frizzled-Dishevelled coupling by phosphatidylinositol-bisphosphate, PREPRINT (Version 1) available at Research Square (2026).
Salipro Biotech to speak at Festival of Biologics 2026
2026-09-22
Salipro Biotech will be presenting at the upcoming Festival of Biologics in Basel, Switzerland (October 13-15).
Our Business Development Director, Peter Jahnmatz will be showcasing the latest advancements enabled by the Salipro® platform through both a talk and a poster presentation.
Join Peter’s presentation on October 15 at 11:20 AM to learn how Salipro helps to transform difficult membrane protein targets into therapeutic opportunities.
We look forward to connecting with partners, collaborators, and fellow scientists at the Festival of Biologics!
See you in Basel!
Salipro Biotech is attending Discovery on Target 2026
2026-09-08
Salipro Biotech is heading to Boston for Discovery on Target 2026 (September 28- October 1)!
Feel free to connect with our Business Development Director, Peter Jahnmatz, to discuss how the Salipro® platform enables your discovery teams to work with challenging membrane proteins, including GPCRs, ion channels, and transporters.
Peter will be presenting a poster at the conference, showcasing the latest advancements of the Salipro® platform in membrane protein drug discovery. Stop by to learn more and discuss how we can support your research efforts against these targets.
We look forward to seeing familiar faces and building new connections at Discovery on Target 2026!